STOCK TITAN

Medicus Pharma Ltd. (MDCX) 424B Filings

MDCX NASDAQ

Here are the 424B prospectus supplements from Medicus Pharma Ltd. (MDCX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow MDCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDCX filings page.

Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) filed a prospectus supplement covering 64,911 common shares issuable upon exercise of warrants, updating its prospectus with its November 19, 2026 current report.

The Public Warrants have a $4.64 exercise price and expire November 15, 2029. Nasdaq lifted the deficiency under its $35 million Market Value of Listed Securities requirement after Medicus demonstrated compliance with the alternative $2.5 million shareholders’ equity requirement, giving effect to transactions described in its November 16, 2026 report. The notice makes continued compliance conditional on evidence of the equity requirement in the next periodic report for the period ending December 31, 2026; if Medicus does not evidence compliance, it may be subject to delisting.

Rhea-AI Summary

Medicus Pharma Ltd.'s prospectus supplement covers 64,911 common shares issuable upon exercise of warrants and incorporates the company's November 13, 2026 current-report update.

Medicus exchanged $10.5 million of A-1 Note principal for 105,000 non-convertible, non-voting preferred shares at $100 each; the exchanged debt was extinguished, with no cash proceeds to the company. The preferred shares carry cumulative 8% annual dividends payable in kind. A separate registered direct offering closed with approximately $3.0 million in gross proceeds before expenses, excluding warrant-exercise proceeds; the company also completed private placements for approximately $1.25 million and ATM sales for approximately $0.35 million.

After these transactions, the company estimated unaudited pro forma shareholders' equity of approximately $3.0 million as of November 13, 2026, and believes it met Nasdaq's $2.5 million Equity Standard. Nasdaq had not confirmed compliance; the company may be subject to delisting if it does not evidence compliance at its next periodic report. Medicus also cited substantial doubt about its ability to continue as a going concern.

Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) is offering 97,973 common shares and pre-funded warrants to purchase up to 1,646,213 common shares, at $1.72 per share and $1.7199 per warrant. Each warrant covers one share, is immediately exercisable at $0.0001 per share, and carries a 4.99% beneficial-ownership limit, or 9.99% at the holder’s election. Gross proceeds are approximately $3.0 million before expenses, excluding warrant-exercise proceeds.

Closing depends on a concurrent private placement of 726,730 shares for approximately $1.25 million, including at least $1.1 million in gross cash proceeds at no less than $1.72 per share, funded from purchasers’ own resources rather than conversion or cancellation of company obligations. Separately, Streeterville exchanged $10.5 million principal under the A-1 Note for 105,000 non-convertible, non-voting preferred shares; the exchanged debt was extinguished, and the preferred shares carry cumulative 8% dividends payable in kind.

Medicus disclosed substantial doubt about its ability to continue as a going concern. As of September 30, 2026, it had approximately $5.0 million in cash and equivalents, $8.1 million in restricted cash and $21.0 million in debentures and secured notes by carrying amount. The company says the offering and private-placement proceeds, together with existing cash, will not fund planned operations for an extended period and that it needs substantial additional capital.

Rhea-AI Summary

Medicus Pharma Ltd. supplements its prospectus with 3,245,595 common shares issuable upon exercise of warrants. Its Public Warrants carry a $4.64 exercise price and expire November 15, 2029. For the nine months ended September 30, 2026, Medicus recorded a net loss of $35.9 million, compared with $27.3 million in 2025, and used $31.9 million in operating cash, versus $16.2 million. At September 30, cash and cash equivalents were $5.0 million and restricted cash was $8.1 million; the restricted funds were not available for general corporate purposes except under the financing arrangements.

The company disclosed substantial doubt about its ability to continue as a going concern within one year after the financial statements are issued, citing continued losses and outstanding debt obligations. It expects significant operating losses and may never become profitable. Under its Pfizer agreement, Medicus paid $12.0 million upfront for CD228V rights; a $2.0 million development funding payment reduced the related acquired IPR&D expense to $10.0 million. A further $15.0 million payment is scheduled for September 2, 2027, unless the company exercises its termination right under the stated conditions. Third-quarter net loss was $15.2 million versus $16.0 million a year earlier.

Rhea-AI Summary

Medicus Pharma Ltd.'s prospectus supplement identifies 64,911 common shares issuable upon exercise of warrants and updates the existing prospectus with information from the company's October 23, 2026 current report. The warrants have a $4.64 exercise price and expire November 15, 2029. On October 22, 2026, the last reported prices were $2.62 for common shares and $0.21 for Public Warrants.

Nasdaq notified Medicus on October 23, 2026 that it had regained compliance with the $1.00 minimum bid price requirement: closing bids were at least $1.00 for ten consecutive business days, from October 12 through October 23, and Nasdaq closed the matter. The notice superseded an October 20 delisting determination. Medicus stated that there can be no assurance it will maintain compliance with this or Nasdaq's other continued listing requirements.

Rhea-AI Summary

Medicus Pharma Ltd. supplements its prospectus covering 64,911 common shares issuable upon exercise of warrants and reports a 1-for-50 share consolidation, effective October 12, 2026. The common shares began trading on a post-consolidation basis on The Nasdaq Capital Market that day. Shareholders approved a consolidation of up to 1-for-50 at the June 3, 2026 meeting, and the board approved the 1-for-50 ratio on September 24, 2026. Every 50 issued and outstanding common shares became one new common share; the consolidation did not modify common-share rights or preferences. Proportionate adjustments were made to exercise or conversion prices and the number of common shares underlying outstanding equity awards, convertible securities, warrants, and equity incentive plans. Fractional shares were rounded down, with cash paid in lieu.

Rhea-AI Summary

Medicus Pharma Ltd.'s prospectus identifies 3,245,595 common shares issuable upon exercise of warrants. The company announced a 50-to-one consolidation of its common shares, effective October 12, 2026. Each 50 issued and outstanding common shares will be exchanged for one new common share, and the ticker symbol will remain MDCX.

No fractional shares will be issued; holders otherwise entitled to a fraction will be rounded down and paid cash in lieu. The company also stated that exercise prices and share counts for outstanding equity awards, convertible securities and warrants will be adjusted proportionately. The company said the consolidation is intended to increase the bid price and enable it to regain compliance with Nasdaq's minimum bid price requirement.

Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) filed a prospectus supplement covering 3,245,595 common shares issuable upon exercise of outstanding public warrants at $4.64 per share, expiring November 15, 2029. The supplement incorporates two recent current reports into the existing Form S-1 prospectus.

On September 4, 2026, officers and employees elected to take approximately $1.45 million of cash bonuses in equity, and the company issued an aggregate 8,529,412 restricted common shares based on a Nasdaq closing price of $0.1705 per share. Separately, on September 11, 2026, Medicus Pharma and YA II PN, LTD. mutually terminated a Standby Equity Purchase Agreement that had permitted up to $15.0 million of common share sales, with no borrowings outstanding and no termination fees due.

Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) filed a prospectus supplement registering 3,245,595 common shares issuable upon exercise of outstanding warrants and updating investors with a new collaboration disclosure. The attached Form 8-K describes a Co-Development and License Agreement under which Pfizer granted Medicus exclusive, worldwide rights to develop and commercialize CD228V, an early clinical-stage antibody-drug conjugate targeting melanotransferrin (CD228). Medicus paid Pfizer a $12.0 million upfront fee, will owe an additional $15.0 million on the first anniversary, and received a $2.0 million Development Funding Payment to support CD228V development. Pfizer remains economically involved through potential development, regulatory and sales milestones that in aggregate exceed $1.0 billion and through low double-digit royalties on annual net sales, while Medicus retains control over development, regulatory and commercialization activities.

Rhea-AI Summary

Medicus Pharma Ltd. is registering 3,245,595 common shares issuable upon exercise of outstanding warrants, each with a $4.64 exercise price and expiring November 15, 2029. Common shares and public warrants trade on Nasdaq as MDCX and MDCXW.

For the quarter ended June 30, 2026, Medicus reported a net loss of $11.7 million, and a six‑month loss of $20.7 million, driven by $20.1 million in operating expenses, including increased R&D for SkinJect and Teverelix. Cash and cash equivalents were $15.2 million with an additional $10.0 million of restricted cash; total assets were $27.1 million and total liabilities $28.8 million, resulting in negative shareholders’ equity of $(1.7) million.

Financing inflows for the first half of 2026 included $22.0 million of secured promissory notes, $12.4 million from an at‑the‑market program, and $4.1 million via a standby equity purchase agreement. Management discloses substantial doubt about the company’s ability to continue as a going concern without additional capital and notes a Nasdaq notice for not meeting the $1.00 minimum bid price requirement.

Rhea-AI Summary

Medicus Pharma Ltd. files a prospectus supplement amending its Form S-1 to register 3,245,595 Common Shares issuable upon exercise of outstanding warrants. The supplement incorporates a Form 8-K dated June 3, 2026 and updates offering and corporate information.

The Public Warrants have an exercise price of $4.64 and an expiration date of November 15, 2029. The prospectus notes last reported sales prices on June 3, 2026 of the common shares at $0.3576 and the Public Warrants at $0.50. The attached Form 8-K reports shareholders ratified KPMG, elected nine directors, and approved a potential share consolidation of up to 50 pre-consolidation for 1 post-consolidation share.

Rhea-AI Summary

Medicus Pharma Ltd. registers 3,245,595 common shares issuable upon the exercise of warrants. This prospectus supplement dated May 27, 2026 amends the Form S-1 prospectus and incorporates a Form 8-K describing a note financing and Nasdaq notice.

The Form 8-K discloses a note purchase agreement with Streeterville Capital providing a Secured Promissory Note A-1 with an original principal of $12,864,225 (including an OID of $834,225) and a Secured Promissory B Note of $10,000,000. The Company states proceeds will support clinical programs, business development and general corporate purposes, and used approximately $2.5 million to repay a prior debenture. The Company also received a Nasdaq notice for noncompliance with the $35,000,000 MVLS standard and has a 180-calendar-day period to regain compliance, until November 16, 2026.

Rhea-AI Summary

Medicus Pharma Ltd. registers 3,245,595 common shares issuable upon exercise of warrants. This prospectus supplement (dated May 14, 2026) amends the existing prospectus and incorporates the Company's Form 10-Q for the quarter ended March 31, 2026. The supplement records the number of common shares that may be issued if outstanding warrants are exercised and updates investors with interim financials.

The attached Form 10-Q shows 56,658,164 common shares issued and outstanding as of May 7, 2026, cash of $6,365,624 at March 31, 2026, a three-month net loss of $9,042,311, and a working capital balance of $1,328,773. Management discloses substantial doubt about the Company's ability to continue as a going concern within one year.

Rhea-AI Summary

Medicus Pharma Ltd. files a prospectus supplement to register 3,245,595 common shares issuable upon the exercise of outstanding public warrants. The supplement attaches Amendment No. 1 to the 2025 Form 10-K, which adds Part III disclosures including director and executive officer biographies, board and committee composition, executive compensation tables, and governance policies.

The prospectus notes the Public Warrants carry a $4.64 exercise price and expire November 15, 2029; last reported April 28, 2026 prices were $0.30 per common share and $0.7199 per Public Warrant. Shares outstanding were 41,818,092 as of April 15, 2026.

Rhea-AI Summary

Medicus Pharma Ltd. filed a Prospectus Supplement No. 1 and attached a Form 8-K to register 3,245,595 common shares issuable upon the exercise of warrants. The supplement reflects an ATM Upsize: the company amended its Equity Distribution Agreement to permit up to $50,000,000 of at-the-market sales and states it has raised approximately $11.5 million under the ATM Offering Program. The filing discloses last reported sales prices of the common shares at $0.3321 and Public Warrants at $0.2901. The company also received Nasdaq notice for noncompliance with the minimum $1.00 bid-price rule and has until October 19, 2026 to regain compliance.

Rhea-AI Summary

MDCX amends its prospectus supplement to offer common shares having an aggregate offering price of up to $50,000,000 under an amended equity distribution agreement dated April 23, 2026. The Sales Agreement names Maxim Group LLC and Yorkville Securities, LLC as Agents. The company’s common shares trade on Nasdaq under MDCX; the prospectus cites a closing share price of $0.339 and Public Warrants closing at $0.2901 as of April 22, 2026.

Rhea-AI Summary

Medicus Pharma Ltd. registers up to 1,397,184 common shares via a prospectus supplement to its Form S-1, and this supplement incorporates the Form 10-K filed on March 25, 2026. The supplement updates the offering materials and amends the Prospectus effective November 14, 2025.

The Form 10-K included by reference summarizes Medicus’s operations, including completion of the Antev acquisition for approximately $2.97M plus 1,603,164 shares, clinical progress for D-MNA (Phase 2 topline results) and regulatory clearances and study-may-proceed letters for its Teverelix programs.

Rhea-AI Summary

Medicus Pharma Ltd. amends its May 29, 2025 prospectus to register 2,260,000 common shares issuable upon the exercise of outstanding public warrants. The supplement attaches the company's Form 10-K and updates disclosures, including that the public warrants have an exercise price of $4.64 and expire on November 15, 2029. The filing cites last reported sales prices on March 24, 2026 of $0.49 per common share and $0.57 per Public Warrant, and states there were 39,362,109 common shares outstanding as of March 17, 2026. The Form 10-K (fiscal year ended December 31, 2025) also summarizes clinical-stage programs (SkinJect D-MNA and Antev/Teverelix), the August 29, 2025 acquisition of Antev, contingent milestone consideration arrangements, and recent regulatory interactions and topline Phase 2 D-MNA results.

Rhea-AI Summary

Medicus Pharma Ltd. registers 1,115,500 common shares issuable upon the exercise of warrants under a prospectus supplement amending the April 10, 2025 prospectus.

The supplement attaches the Form 10-K for the fiscal year ended December 31, 2025 and updates related disclosures. The Public Warrants have an exercise price of $4.64 and an expiration date of November 15, 2029. The common shares and Public Warrants trade on Nasdaq under the symbols MDCX and MDCXW. Shares outstanding were 39,362,109 common shares as of March 17, 2026.

Rhea-AI Summary

Medicus Pharma Ltd. registers up to 7,500,000 common shares via a prospectus supplement to its effective Registration Statement on Form S-1.

The supplement incorporates the Company’s Form 10-K filed March 25, 2026, and notes 39,362,109 common shares outstanding as of March 17, 2026. The Company’s common shares trade on Nasdaq under the symbol MDCX; the last reported sales price on March 24, 2026 was $0.49.

Rhea-AI Summary

Medicus Pharma Ltd. registers 1,115,500 common shares issuable upon the exercise of warrants, as set forth in Prospectus Supplement No. 22 dated March 6, 2026. The supplement attaches a Current Report on Form 8-K and updates the April 10, 2025 prospectus.

The supplement restates the Public Warrants' exercise price $4.64 and expiration date November 15, 2029, and notes last reported Nasdaq prices on March 5, 2026 of $0.68 (common share) and $1.00 (Public Warrant). The Form 8-K discloses prior unregistered sales under a SEPA to YA II PN, Ltd. totaling 4,471,038 common shares for aggregate consideration of $3,846,910, and that part of those proceeds prepaid a Yorkville debenture.

Rhea-AI Summary

Medicus Pharma Ltd. files a prospectus supplement registering up to 1,397,184 common shares and amends the Prospectus dated November 14, 2025 to incorporate its Form 8-K dated March 6, 2026. The supplement notes the company completed multiple unregistered sales to Yorkville under a Standby Equity Purchase Agreement, totaling $3,846,910 for 4,471,038 common shares as detailed in the attached table.

Rhea-AI Summary

Medicus Pharma Ltd. registers 2,260,000 common shares issuable upon the exercise of public warrants under a prospectus supplement dated March 6, 2026. This supplement amends the May 29, 2025 prospectus and incorporates a Form 8-K filed March 6, 2026.

The Form 8-K discloses prior sales under a Standby Equity Purchase Agreement totaling 4,471,038 common shares for aggregate consideration of $3,846,910 (sales dated December 19, 2025 through March 6, 2026). The supplement notes the public warrants have an exercise price of $4.64 and expire on November 15, 2029; market prices quoted were $0.68 per common share and $1.00 per Public Warrant as of March 5, 2026.

Rhea-AI Summary

Medicus Pharma Ltd. files a prospectus supplement registering up to 7,500,000 common shares and attaches a Form 8-K reporting equity financings under a Standby Equity Purchase Agreement.

The Form 8-K lists completed SEPA sales totaling 4,471,038 common shares for aggregate consideration of $3,846,910, and states Yorkville may purchase additional shares "subject to the satisfaction or waiver of the conditions and limitations set forth in the SEPA". The company notes its Nasdaq last sale price was $0.68.

Rhea-AI Summary

Medicus Pharma Ltd. filed a prospectus supplement covering the resale of up to 2,680,000 common shares tied to previously issued warrants. The supplement adds information from a new current report about a warrant inducement agreement and recent equity sales.

On December 5, 2025 the company agreed with an accredited institutional holder to amend existing warrants for up to 2,680,000 common shares to an exercise price of $1.92 per share. In return, the holder will receive new unregistered warrants for up to 4,020,000 additional common shares at $2.00 per share, expiring on June 5, 2031, with one series allowing the company to force exercise if the 10‑day average VWAP reaches $10.00. Gross proceeds from the exercise of the existing warrants are expected to be approximately $5.1 million, before expenses and a 6.0% cash fee to Maxim Group LLC.

The company plans to register the resale of the shares underlying the new warrants by filing a new registration statement within 60 days and keeping it effective until the original holder can sell under Rule 144 without limits. Separately, under its Standby Equity Purchase Agreement with Yorkville, Medicus Pharma sold 680,893 common shares for aggregate consideration of $1,500,905 and used part of the net proceeds to prepay a portion of an outstanding debenture. Its common shares trade on the Nasdaq Capital Market under the symbol MDCX, with a last reported price of $2.05 on December 5, 2025.

Rhea-AI Summary

Medicus Pharma Ltd. has filed a prospectus supplement relating to 1,115,500 common shares issuable upon the exercise of previously registered warrants and uses it to update investors on new financing activity. The company entered into a warrant inducement agreement with an institutional holder to amend existing warrants to buy up to 2,680,000 common shares at $1.92 per share, in exchange for the holder receiving 4,020,000 new unregistered warrants with a $2.00 exercise price, expiring June 5, 2031. One series of these new warrants allows the company, under certain conditions, to force exercise if the average share VWAP reaches $10.00 over ten trading days, and the company expects approximately $5.1 million in gross proceeds from the existing warrant exercises before a 6% fee to its advisor.

The filing also details recent sales of 680,893 common shares to Yorkville under a standby equity purchase agreement, generating about $1,500,905 in aggregate consideration, with part of the net proceeds used to prepay a portion of a debenture owed to Yorkville. Medicus plans to register the resale of the shares underlying the new warrants in a future registration statement and notes that the new warrants and related shares are currently unregistered, issued under a private offering exemption.

Rhea-AI Summary

Medicus Pharma Ltd. updates its prospectus for an offering of up to 2,680,000 common shares and attaches a recent current report. The supplement incorporates a Form 8-K that details executive leadership changes while keeping the original S-1 prospectus in effect.

The company’s common shares trade on Nasdaq under the symbol MDCX, with a last reported price of $1.73 on December 3, 2025. The filing confirms Medicus Pharma’s status as an emerging growth company and reminds investors of the high risks described in the underlying prospectus.

The Form 8-K reports that Chief Financial Officer James Quinlan resigned as an officer and employee effective November 28, 2025, after being on medical leave since September 12, 2025. Effective December 1, 2025, President Carolyn Bonner, who had been acting CFO, was appointed Chief Financial Officer and will continue serving as President under a five-year employment agreement with a $395,000 base salary and escalating target bonus opportunities.

Rhea-AI Summary

Medicus Pharma Ltd. has filed a prospectus supplement covering up to 3,710,000 common shares under an existing S-1 registration and attached its latest quarterly report. For the nine months ended September 30, 2025, the company reported a net loss of $27,259,804, driven by operating expenses of $26,568,702, including an $8,717,475 in-process R&D charge for the Antev Teverelix acquisition. Cash and cash equivalents were $8,662,091, with total assets of $9,977,661 and a shareholders’ deficit of $804,890. A going concern warning highlights reliance on continued financings, including an $8,000,000 debenture and a $15,000,000 standby equity purchase agreement, while common shares outstanding reached 22,029,144 as of November 11, 2025.

Rhea-AI Summary

Medicus Pharma Ltd. has filed a prospectus supplement registering up to 1,397,184 common shares and incorporating its latest quarterly report. The company is a clinical-stage biotech developing dissolvable microneedle patches for skin cancers and, through newly acquired Antev, a GnRH antagonist (Teverelix) for prostate-related indications.

As of September 30, 2025, Medicus held $8.7 million in cash and total assets of about $10.0 million, but current liabilities of $10.7 million left shareholders with a deficit of roughly $0.8 million. There were 22,029,144 common shares outstanding as of November 11, 2025, and the Nasdaq share price was $2.26 on November 13, 2025.

The company reported a net loss of $15.98 million for the quarter and $27.26 million for the nine months ended September 30, 2025, driven by higher general and administrative and R&D spending and an $8.72 million in-process R&D charge related to Teverelix. Operations have been funded by equity offerings, warrant exercises, a standby equity purchase agreement and new debentures, and management discloses substantial doubt about the ability to continue as a going concern without additional capital.

Rhea-AI Summary

Medicus Pharma Ltd. is registering 2,260,000 common shares issuable upon the exercise of warrants under its Form S-1, via a new prospectus supplement that incorporates its Quarterly Report on Form 10-Q for the period ended September 30, 2025. The company reported a net loss attributable to common shareholders of $20,935,830 for the quarter and $32,214,322 for the nine months, driven by higher general and administrative costs, increased research and development spending, and an $8,717,475 charge for in-process R&D from the Antev acquisition. Cash and cash equivalents were $8,662,091 with debentures of $6,785,812 and a shareholders’ deficit of $804,890. The company discloses substantial doubt about its ability to continue as a going concern and highlights reliance on warrant exercises, a standby equity purchase agreement and other financings. As of November 11, 2025, it had 22,029,144 common shares outstanding.

Rhea-AI Summary

Medicus Pharma Ltd. is registering 1,115,500 common shares issuable upon exercise of existing public warrants. The warrants have a $4.64 exercise price and expire on November 15, 2029, while the common shares and warrants trade on Nasdaq under "MDCX" and "MDCXW." As of November 11, 2025, the company had 22,029,144 common shares outstanding.

For the nine months ended September 30, 2025, Medicus reported a net loss of $27.3 million, driven by $26.6 million in operating expenses, including $12.7 million in general and administrative costs, $5.1 million in R&D, and an $8.7 million in-process R&D charge from the Antev acquisition. Shareholders’ equity shifted to a deficit of about $0.8 million despite multiple equity raises and warrant exercises.

Cash and cash equivalents were $8.7 million against a working capital deficit and debentures of $6.8 million. Management discloses substantial doubt about the company’s ability to continue as a going concern and highlights reliance on additional financings, including a standby equity purchase agreement of up to $15 million, warrant exercises, and other capital sources to fund ongoing clinical programs.

Rhea-AI Summary

Medicus Pharma Ltd. has filed a prospectus supplement covering up to 7,500,000 common shares under its Form S-1, updating the offering with new quarterly information. The attached Form 10-Q shows a clinical-stage biotech expanding its pipeline but generating substantial losses as it funds development and acquisitions.

For the nine months ended September 30, 2025, the company recorded a net loss of $27,259,804, driven by $26,568,702 in operating expenses that include $8,717,475 of in-process R&D expense from the Antev acquisition, higher general and administrative costs, and increased research and development spending. Cash and cash equivalents were $8,662,091 as of September 30, 2025.

Medicus raised capital through a Regulation A unit offering, a June 2025 public offering, warrant exercises, a standby equity purchase agreement and new debentures, but still reported a shareholders’ deficit and a working capital deficit. The company discloses substantial doubt about its ability to continue as a going concern without additional financing. As of November 11, 2025, it had 22,029,144 common shares issued and outstanding.

Rhea-AI Summary

Medicus Pharma filed a prospectus supplement to its Form S-1 covering up to 3,710,000 common shares. The supplement attaches a Current Report on Form 8-K.

The 8-K details recent sales of 1,088,048 common shares to Yorkville under the Standby Equity Purchase Agreement, for approximate aggregate consideration of $2,526,364, across multiple issuances from September 8 to October 16, 2025. The company states it has used part of the net proceeds to prepay a portion of a debenture outstanding with Yorkville.

Medicus Pharma’s common shares trade on Nasdaq as MDCX; the last reported sales price was $2.41 on October 16, 2025. The company is an emerging growth company under SEC rules.

Rhea-AI Summary

Medicus Pharma filed a prospectus supplement covering 2,260,000 common shares issuable upon the exercise of warrants. The company’s common shares and the public warrants (exercise price $4.64, expiring November 15, 2029) trade on Nasdaq as MDCX and MDCXW. On October 16, 2025, the last reported prices were $2.41 for the shares and $0.90 for the warrants.

Attached, a Current Report details recent sales under a Standby Equity Purchase Agreement with Yorkville. Between September 8 and October 16, 2025, the company sold 1,088,048 common shares to Yorkville for aggregate consideration of $2,526,364, in transactions exempt from registration under Section 4(a)(2). The company used part of the net proceeds to prepay a portion of a debenture outstanding with Yorkville.

Rhea-AI Summary

Medicus Pharma Ltd. filed a prospectus supplement updating its S-1 to cover 1,115,500 common shares issuable upon the exercise of warrants. The supplement incorporates a new Form 8-K.

The company also reported under the SEPA with Yorkville that it sold 1,088,048 common shares across multiple dates for approximately $2,526,364 in aggregate consideration, and used part of the net proceeds to prepay a portion of a debenture with Yorkville. The common shares and public warrants trade on Nasdaq as MDCX and MDCXW; on October 16, 2025, last reported prices were $2.41 and $0.90, respectively. The public warrants have a $4.64 exercise price and expire on November 15, 2029.

Rhea-AI Summary

Medicus Pharma Ltd. (Nasdaq: MDCX) has entered into a warrant-inducement transaction designed to raise near-term cash and expand its future capital pool.

  • Immediate cash: A single accredited holder agreed to exercise 1,340,000 existing $2.80 warrants, delivering approximately $3.75 million gross proceeds (closing expected 14 July 2025). Maxim Group will receive a 6 % cash fee.
  • New leverage: In exchange, the holder will receive 2,680,000 five-year “New Warrants” at an exercise price of $3.75. Half the series includes a forced-exercise feature once the 10-day VWAP equals or exceeds $10.00.
  • Protective terms: New Warrants contain customary anti-dilution adjustments and Black-Scholes value protection on fundamental transactions.
  • Additional financing: Through two SEPA draws (9 & 14 July 2025) the company sold 490,000 shares to Yorkville at an average price of $3.10, raising $1.52 million earmarked partly for debenture pre-payment.
  • Use of proceeds: funds will support ongoing clinical trials, working capital and the pending acquisition of Antev Limited.
  • Listing/Capital structure: Common shares and $4.64 Public Warrants continue to trade under MDCX and MDCXW. The inducement and SEPA transactions add up to 4.51 million potential new shares, increasing prospective dilution.

Medicus remains an emerging growth company and intends to register New Warrant shares within 120 days.

Rhea-AI Summary

Transaction overview: On July 14, 2025 Medicus Pharma (Nasdaq: MDCX) entered a Warrant Inducement Agreement with an accredited holder. The holder will immediately exercise 1,340,000 existing warrants at $2.80, generating roughly $3.75 million gross proceeds. In exchange, the investor will receive 2,680,000 new five-year warrants exercisable at $3.75; half include a forced-exercise clause if the 10-day VWAP reaches $10.

The company will pay Maxim Group a 6 % cash fee and intends to allocate net proceeds to ongoing clinical trials, working capital and costs linked to its pending Antev Limited acquisition.

Additional financing: Separately, Medicus sold 490,000 common shares to Yorkville under its Standby Equity Purchase Agreement at an average $3.11 per share, raising $1.52 million earmarked partly for debenture pre-payment.

Capital structure impact: The transactions immediately issue 1.34 million shares and could add up to 2.68 million more upon warrant exercise, plus the 0.49 million SEPA shares—an aggregate potential dilution of ~4.51 million shares, or roughly 10 % of the pre-deal share count (exact base not disclosed). The new warrants are struck 24 % above the last close ($3.03) and may provide further cash if exercised.

Nasdaq prices on 11-Jul-25: common $3.03, public warrants $1.03. The company remains an emerging growth company and will file an S-1 within 120 days to register the resale of the new warrant shares.

Rhea-AI Summary

Medicus Pharma announced the appointment of Andrew Smith (57) as Chief Operating Officer, effective June 30, 2025. The company filed a prospectus supplement regarding up to 3,710,000 common shares trading on Nasdaq under symbol MDCX at a last reported price of $2.49 on June 20, 2025.

Key details of Smith's appointment:

  • Brings 30+ years of experience in asset management and financial operations
  • Annual base salary: $325,000
  • Stock option grant: 100,000 shares at $2.60 strike price, vesting quarterly over 5 years
  • Previous roles include CEO of SR Asset Management and senior positions at Aberdeen Asset Management
  • Holds Executive MBA from INSEAD and HND in Accounting from Glasgow College of Commerce

The company is classified as an emerging growth company, eligible for reduced public company disclosure requirements. The filing includes standard risk disclaimers and confirms no reportable related-party transactions with Smith.

Rhea-AI Summary

Medicus Pharma announced the appointment of Andrew Smith (57) as Chief Operating Officer, effective June 30, 2025. The filing details a prospectus supplement covering 2,260,000 common shares issuable upon warrant exercise at $4.64 per share, expiring November 15, 2029.

Key appointment details:

  • Annual base salary: $325,000
  • Stock option grant: 100,000 shares at $2.60 strike price, vesting quarterly over 5 years
  • Extensive experience: Over 30 years in asset management and financial operations
  • Previous roles: CEO of SR Asset Management, COO at Aberdeen Asset Management

Trading information: As of June 20, 2025, MDCX shares traded at $2.49 and warrants (MDCXW) at $0.80 on Nasdaq Capital Market. The company is classified as an emerging growth company under SEC rules.

Rhea-AI Summary

Medicus Pharma has filed a prospectus supplement (424B3) related to 1,115,500 common shares issuable upon warrant exercise. The company has appointed Andrew Smith as Chief Operating Officer, effective June 30, 2025.

Key details of the filing include:

  • Public Warrants are exercisable at $4.64 with expiration on November 15, 2029
  • Current trading prices as of June 20, 2025: Common shares at $2.49, Warrants at $0.80
  • Smith's compensation package includes $325,000 annual base salary and 100,000 stock options at $2.60 strike price, vesting quarterly over 5 years

Smith brings over 30 years of experience, previously serving as CEO of SR Asset Management and holding leadership positions at Aberdeen Asset Management. The company is listed on Nasdaq Capital Market under symbols MDCX (shares) and MDCXW (warrants) and qualifies as an emerging growth company.

Rhea-AI Summary

Medicus Pharma Ltd. (NASDAQ: MDCX) has filed Prospectus Supplement No. 6 to its April 10, 2025 S-1, attaching a Form 8-K dated June 17, 2025. The filing discloses the issuance of a third and final debenture to YA II PN, Ltd. (Yorkville) under the previously announced $5 million securities purchase agreement.

Key terms of the third debenture

  • Principal amount: $2.5 million (remaining capacity under the agreement)
  • Net proceeds to Medicus: $2.25 million
  • Interest: 8.0% per annum, rising to 18.0% upon certain defaults
  • Maturity: February 2, 2026
  • Guaranteed by all company subsidiaries via a global guaranty agreement

This draws total funding under the Yorkville facility to its full $5 million principal, delivering $4.5 million in aggregate net cash since May 2025. The company characterises itself as an emerging growth company and warns investors of high risk, pointing to detailed risk factors in the base prospectus.

The common shares and public warrants (exercise price $4.64; expiry Nov 15 2029) remain listed on the Nasdaq Capital Market, last trading at $2.58 and $0.80, respectively, on June 18 2025.

Implications for investors: the completed financing strengthens short-term liquidity and funds ongoing operations, but adds leverage and exposes Medicus to higher coupon costs and covenant-linked default rate escalation. Guaranteeing subsidiaries also elevates secured creditor priority over equity holders.